Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Cardiomyopathy, Dilated

ClinicalTrials.gov lists 242 trials for Cardiomyopathy, Dilated or a narrower condition beneath it. LoneStar Heart, Inc. has the most among industry and government lead sponsors, with 4.

MeSH D002311 Cardiovascular Diseases C14 C16 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 13 Phase 1/2 Phase 1/2 14 Phase 2 Phase 2 25 Phase 2/3 Phase 2/3 7 Phase 3 Phase 3 15 Phase 4 Phase 4 9 Not applicable Not applicable 59 Observational Observational 100 Phase 1 Phase 1 13 Phase 1/2 Phase 1/2 14 Phase 2 Phase 2 25 Phase 2/3 Phase 2/3 7 Phase 3 Phase 3 15 Phase 4 Phase 4 9 Not applicable Not applicable 59 Observational Observational 100

Trials per phase

242 of the 242 trials are tagged with Cardiomyopathy, Dilated itself; the rest are tagged with a narrower condition beneath it.

Get the Cardiomyopathy, Dilated report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Cardiomyopathy, Dilated trials start? (29)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 17

1992: 1 trials (Observational 1) 1994: 1 trials (Phase 2 1) 2000: 2 trials (Not applicable 1, Phase 4 1) 2001: 1 trials (Observational 1) 2002: 1 trials (Observational 1) 2003: 4 trials (Not applicable 2, Phase 4 1, Phase 1/2 1) 2004: 5 trials (Observational 2, Not applicable 1, Phase 1/2 2) 2005: 5 trials (Observational 3, Phase 4 1, Phase 2/3 1) 2006: 6 trials (Observational 1, Phase 4 2, Phase 3 2, Phase 2 1) 2007: 14 trials (Observational 5, Not applicable 4, Phase 3 2, Phase 1/2 2, Phase 1 1) 2008: 11 trials (Observational 2, Not applicable 3, Phase 3 3, Phase 2 2, Phase 1 1) 2009: 7 trials (Observational 2, Not applicable 2, Phase 2 3) 2010: 6 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 2 1, Phase 1/2 1) 2011: 12 trials (Observational 2, Not applicable 5, Phase 3 1, Phase 2 3, Phase 1/2 1) 2012: 6 trials (Observational 2, Phase 4 1, Phase 2/3 1, Phase 1/2 1, Phase 1 1) 2013: 9 trials (Observational 7, Not applicable 1, Phase 1/2 1) 2014: 16 trials (Observational 7, Not applicable 3, Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1 1) 2015: 6 trials (Observational 2, Not applicable 2, Phase 2/3 1, Phase 2 1) 2016: 12 trials (Observational 5, Not applicable 3, Phase 4 1, Phase 2/3 2, Phase 2 1) 2017: 7 trials (Observational 3, Not applicable 2, Phase 1 2) 2018: 14 trials (Observational 8, Not applicable 2, Phase 3 2, Phase 2 1, Phase 1/2 1) 2019: 16 trials (Observational 9, Not applicable 4, Phase 2/3 1, Phase 2 2) 2020: 17 trials (Observational 5, Not applicable 7, Phase 3 1, Phase 2 4) 2021: 8 trials (Observational 5, Not applicable 2, Phase 1 1) 2022: 10 trials (Observational 5, Not applicable 3, Phase 3 1, Phase 2 1) 2023: 8 trials (Observational 5, Not applicable 1, Phase 3 1, Phase 1 1) 2024: 12 trials (Observational 5, Not applicable 4, Phase 4 1, Phase 3 1, Phase 1 1) 2025: 11 trials (Observational 4, Not applicable 3, Phase 2 1, Phase 1/2 1, Phase 1 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 11
2025 11
2024 12
2023 8
2022 10
2021 8
2020 17
2019 16
2018 14
2017 7

Showing 10 of 29 earlier years.

Start your 14-day trial Email me all 29 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 15 trials starting in 2026 and about 14 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 21 trials still running at the 2026-10-09 snapshot; registered median of 33 months across 113 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Cardiomyopathy, Dilated trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 13
Phase 1/2 14
Phase 2 25
Phase 2/3 7
Phase 3 15
Phase 4 9
Not applicable 59
Observational 100

How many Cardiomyopathy, Dilated trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 5
Recruiting 43
Enrolling by invitation 3
Active, not recruiting 10
Completed 97

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Cardiomyopathy, Dilated trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
LoneStar Heart, Inc. 4
Ancora Heart, Inc. 3
AstraZeneca 3
Institut National de la Santé Et de la Recherche Médicale, France 3
Ministry of Health, Brazil 3

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Cardiomyopathy, Dilated? (1)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Danicamtiv 2

Interventions as named in the registry (14)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
FAP immunosuppressive CAR-DC 2
Carvedilol CR 2
Allopurinol Pill 2
Metoprolol XL 2
ARRY-371797, p38 inhibitor, oral 2

Showing 5 of 14 interventions.

Start your 14-day trial Email me all 14 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Cardiomyopathy, Dilated trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Death 32 3
Ventricular tachycardia 17 4
Cardiac failure 16 3
Major Bleeding 15 1
Cardiac failure congestive 12 4

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Cardiomyopathy, Dilated? (507)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy. Circulation. Heart failure 2025 Yes
Left Ventricular Unloading in Nonischemic Dilated Cardiomyopathy Improves Coronary Haemodynamic Reserve. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2025 Yes
Alcohol Exposure Among Patients With Dilated Cardiomyopathy and Their First-Degree Relatives: The DCM Precision Medicine Study. Circulation. Genomic and precision medicine 2025 Yes
The Cardiovascular Magnetic Resonance Phenotype of Lamin Heart Disease. JACC. Cardiovascular imaging 2025 Yes
Antecedent Flu-Like Illness and Onset of Idiopathic Dilated Cardiomyopathy: The DCM Precision Medicine Study. Circulation. Heart failure 2025 Yes

Showing 5 of 507 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Dilated cardiomyopathy 217604 Exact Orphadata Science knowledge files, Product 1
Dilated cardiomyopathy 217604 Exact Orphanet Rare Disease Ontology (ORDO)

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and sub-conditions in mesh.

Browse all condition evidence pages